Educational efforts from pharmaceutical providers as well as peer-to-peer sharing should target all areas of the multidisciplinary team in IBD to support confidence in the concept and clinical suitability of biosimilar anti-TNF-α medicines and be able to assuredly convey this information to patients to support successful treatment outcomes. Here, TNF is linked to inflammatory bowel disease.